BioStock: Arcede wants to renew the market for respiratory drugs

Respiratorius spinoff Arcede Pharma is currently in full swing with the preclinical work on the drug candidate RCD405. The company hopes to be able to offer a new, better treatment for COPD and severe asthma than those offered to patients today. BioStock has taken a look at the current treatment landscape to get an understanding of the potential of a drug with a new mode of action.

Read the full article at biostock.se:

https://www.biostock.se/en/2022/08/arcede-wants-to-renew-the-market-for-respiratory-drugs/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se